Decitabine + Gemtuzumab ozogamicin
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myelogenous Leukemia
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome
Trial Timeline
Apr 1, 2009 → Aug 1, 2012
NCT ID
NCT00882102About Decitabine + Gemtuzumab ozogamicin
Decitabine + Gemtuzumab ozogamicin is a phase 2 stage product being developed by Eisai for Acute Myelogenous Leukemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00882102. Target conditions include Acute Myelogenous Leukemia, Myelodysplastic Syndrome.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00882102 | Phase 2 | Completed |
Competing Products
20 competing products in Acute Myelogenous Leukemia